

CELEBRATING

10
YEARS

2014-2024



Implementation Science at CTRIS, NHLBI

Cara C. Lewis, PhD
Deputy Director

CENTER FOR TRANSLATION RESEARCH
AND IMPLEMENTATION SCIENCE
CTRIS



NHLBI Strategic Vision & 4 Mission-Critical Goals



Major Celebrations at NHLBI

NHLBI



NHLBI Strategic Vision Refresh Focus Areas



Harnessing **data science and new technologies** to drive scientific discovery and precision health.



Using novel approaches for **addressing health disparities** and tackling their biological underpinnings for heart, lung, blood diseases, and sleep disorders.



Furthering the science on the **importance of lifestyle** behaviors.



Leveraging the power of **community and patient engagement**.



Supporting **women's health** through the lifespan.



Addressing and reducing the **impact of "place"** (geography, climate, rural/urban, neighborhood) on heart, lung, blood, and sleep health.

Major Celebrations at NHLBI


NHLBI



CTRIS



The NHLBI Strategic Vision Implementation at CTRIS




Core Pillars and Cross-Cutting Themes


1. Implementation Science
2. Health inequities research
3. Meaningful community-engaged research
4. Global Health research

Support Research Training and Career Development in the US and Abroad

NHLBI's Investment in Implementation Science



- NIH investment has increased 5-fold in 10 years
- NHLBI: 13% of share of all NIH IS awards; 4th overall for total costs



- NHLBI investment has increased 4-fold in 10 years
- Share of implementation science competing awards within NHLBI is ~2%

Charting the Future Together

Supporting Dissemination and Implementation Research and Building the Next Generation of Implementation Scientists Through Training and Career Development

Great expectations for next decade

- As part of our enduring principles, NHLBI supports **more than 700** investigator-initiated R01 research grants every year.
- Submit your investigator-initiated R01 applications via the parent announcement ([NIH Research Project Grant - R01](#)) and the Dissemination and Implementation Research – R01 ([DIRH](#))
- Arrange **for technical assistance call with IC's point of contact/Program Official** to discuss your prospective R01 DIRH application




PAR-22-105 Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)

[R01](#)

- [NOFO \(PAR-22-105\)](#) – check for updates before expiration date of May 8, 2025
- Maximum project period, 5 years
- If request direct costs of \$500k or greater in any year, need prior approval. Contact program official at least 6 weeks before submitting application.
- **Foreign Institutions**
 - Non-domestic (non-U.S.) Entities (Foreign Institutions) **are eligible** to apply.
 - Non-domestic (non-U.S.) components of U.S. Organizations **are eligible** to apply.
 - Foreign components, as [defined in the NIH Grants Policy Statement](#), are allowed.



Highly Recommend: **Technical Assistance** **Call with Program Official**



- **One-page overview could include:**
 - Prospective NOFO(s);
 - Specific Aims;
 - Specify Implementation Framework and endpoints
 - Identify dissemination partners
 - Research budget
 - Strategies for recruitment of participants
 - Breadth of experts needed
 - Site locations
 - Be realistic
 - Do not over promise
- **Consider Domains of Evidence that you would address for End Users of Findings (e.g., WHO, MoH, PEPFAR) which may include:**
 - Priority of Problem
 - Balance of benefits and harms
 - Acceptability to key stakeholders
 - Feasibility of Implementation
 - Mechanisms of action
 - Resource requirements, including costs/personnel/partnerships
 - Sustainability strategies
 - Effect on health equity

Fogarty Career Development Programs: K Awards

K43
K01
(US)



Fogarty traditionally offers two mentored global health research career development programs:

Since 1999 – K01 for US investigators

K01

International Research Scientist Development Award (IRSDA)

[PAR-24-113](#) (Independent Clinical Trial Not Allowed)

[PAR-24-114](#) (Independent Clinical Trial Required)

Since 2015 – K43 for Low- and Middle-Income Country (LMIC) investigators

Emerging Global Leader Award (K43)

[PAR-21-252](#) (Independent Clinical Trial Not Allowed)

[PAR-21-251](#) (Independent Clinical Trial Required)

K43 Currently, not active;

Check periodically

K43

for updates

Implementation Research in Familial Hypercholesterolemia

- Familial Hypercholesterolemia (FH) is a common genetic disorder, affecting 1 in 250 people in the U.S., that causes high levels of low-density lipoprotein cholesterol (LDL-C) leading to premature coronary heart disease
- To Improve Case Finding, Cascade Screening, and Treatment
- <https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-22-006.html>

CELEBRATING
10
YEARS